

U.S.S.N 09/942,959
Osbakken *et al.*
PRELIMINARY AMENDMENT



errors. New Claims 93-113 are being added. Included as an attachment is a marked-up version of the amended claims, per 37 CFR §1.121. No new matter has been added. Claims 93-113 read on the elective species.

* * *

Entry of this amendment is respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 39187-1457
Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: 858 450-8400
Facsimile: 858 587-5360
email: sseidman@HEWM.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Osbakken *et al.*
Serial No.: 09/942,959
Conf. No.: 7962
Filed: August 31, 2001
For: *AEROSOLIZED ANTI-
INFECTIVES, ANTI-
INFLAMMATORIES, AND
DECONGESTANTS FOR THE
TREATMENT OF SINUSITIS*
Art Unit: 1616
Examiner: DeWitty, R.


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number
EV175670174US

Date of Deposit April 24, 2003

I hereby certify that this paper is being deposited
with the United States Postal "Express Mail Post
Office to Addressee" Service under 37 CFR
§1.10 on the date indicated above and addressed
to:

Commissioner for Patents,
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Jonathan Ong

ATTACHMENTS TO THE AMENDMENT

Commissioner for Patents
U.S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Dear Sir:

The following attachment is provided:

Marked up claims in accordance with 37 C.F.R §1.121.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Osbakken *et al.*
Serial No.: 09/942,959
Conf. No.: 7962
Filed: August 31, 2001
For: **AEROSOLIZED ANTI-
INFECTIVES, ANTI-
INFLAMMATORIES, AND
DECONGESTANTS FOR
THE TREATMENT OF
SINUSITIS**
Art Unit: 1616
Examiner: DeWitty, R.


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number
EV175670174US

Date of Deposit April 24, 2003

I hereby certify that this paper is being deposited
with the United States Postal "Express Mail Post
Office to Addressee" Service under 37 CFR
§1.10 on the date indicated above and addressed
to:

Commissioner for Patents,
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Jonathan Ong

MARKED UP CLAIMS PURSUANT TO 37 C.F.R. § 1.121


New Claims 93-113 have been added.

Claims 68, 74, and 86 have been amended as follows (additions are
underlined, deletions are [bracketed]):

68. (Amended) The method of claim 67, wherein the composition is
administered via a nebulizer [and] having a nasal adapter.

74. (Amended) The method of claim 67, wherein the pharmaceutical
composition further comprises a second agent, wherein the second agent is
selected from the group consisting of an anti-histamine, a mast cell stabilizer, a
non-antibiotic anti-microbial agent, an anti-leukotriene, an anti-viral, an
antiseptic, a non-steroidal anti-inflammatory, a combination of at least two
antibiotics, an agent for treating nasal polyps, an anticholinergic agent and
combinations thereof.

US 09/942,959
Osobakk n *et al.*
AMENDED CLAIMS



86. (Amended) The method of claim 74, wherein the second agent is a non-antibiotic anti-microbial agent.[, wherein the at least two antibiotics are selected from the group consisting of penicillins, cephalosporins, macrolides, ketolides, sulfonamides, quinolones, aminoglycosides, beta lactam antibiotics, and linezolid.]